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A COST-EFFECTIVENESS ANALYSIS OF ANTIMICROBIAL THERAPY OF 
BLOODSTREAM INFECTIONS TREATMENT IN INTENSIVE CARE UNIT
Omelyanovsky VV, Protsenko DN, Derkach EV, Sveshnikova ND
Russian State Medical University, Moscow, Russia
OBJECTIVES: According to the recent international data, the incidence of blood-
stream catheter—associated infections is 3–8% in the structure of hospital- acquired 
infections in the intensive care units (ICU) and the leading cause of them are Gram 
positive bacteria. In this study we conducted comparative analysis of clinico—eco-
nomic effectiveness of daptomycin (dapto) vs. vancomycin (vanco) usage in treatment 
of patients with MRSA catheter—associated infection in the ICU. METHODS: “Deci-
sion Tree” pharmacoeconomic model was built based on results of international clini-
cal studies and data of routine practice treatment of bloodstream infections in Moscow 
clinics. Two variants of antibacterial treatment of patients with catheter-associated 
infections differing on starting products (dapto or vanco) were assessed. If the ﬁ rst 
line of therapy was ineffective, patients switched over to the second line therapy cover-
ing resistant strains—meropenem and ﬂ uconazole. Direct and indirect medical costs 
were assessed: cost of antibiotics and additional medical treatment, antibacterial 
diagnostic, laboratory and cost of bed-days in ICU and therapeutic department. Costs 
were based on ofﬁ cial data on hospital medical service in municipal Moscow clinics 
and purchasing price on medical products from price list of the biggest Russian phar-
maceutical distributors. Clinical recovery was considered as efﬁ cacy with the goal to 
evaluate cost-effectiveness ratio (CER) of two groups (CERdapto and CERvan accord-
ingly). RESULTS: Better clinical efﬁ cacy in daptomycin group resulted in lower—
needs to change antibiotic in catheter—associated infection treatment in the ICU in 
comparison to vancomycin group. In spite of the higher price of drug, average cost 
of successfully treated patient by daptomycin (CERdapto) was 227,887 RUR/pt in 
compare with CERvan 235,032 RUR/pt. Exchange rate is 1USD = 30 RUR. CON-
CLUSIONS: Good cost-effectiveness ratio in comparison to vancomycin supports use 
of daptomycin as the ﬁ rst line antibacterial therapy in bloodstream catheter—associ-
ated infections.
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COST-EFFECTIVENESS ANALYSIS OF 1 YEAR PEGINTERFERON 
ALFA-2A VERSUS 4 YEARS ENTECAVIR FOR THE TREATMENT OF 
HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA
Chen W
Fudan University, Shanghai, China
OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 1 
year peginterferon alfa-2a compared to 4 years entecavir for the treatment of HBeAg-
positive chronic hepatitis B in China. METHODS: A Markov health-state model was 
designed to evaluate the direct medical costs and outcomes (life-years and QALYs 
gained) of treating HBeAg-positive chronic hepatitis B in China. The model included 
10 health states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg loss, 
CHB with resistance, Compensated cirrhosis, Decompensated cirrhosis, Hepatocel-
lular carcinoma, Liver transplant, Post-liver transplant and death. The model incor-
porates a maximum analysis time horizon of 80 years with yearly cycles. The clinical 
and quality of life data were obtained from published literature and re-conﬁ rmed 
based on a questionnaire survey from a clinical expert panel of 20 hepatitis B special-
ists. From the perspective of China’s health insurance system, cost data was calculated 
based on the published literature about economic burden of chronic hepatitis B. a 
discounting rate at 3% was used to discount utilities and medical costs happened at 
different years. a univariate sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. RESULTS: The model results showed that 
the utilization of 1 year peginterferon alfa-2a treatment for HBeAg-positive CHB can 
prolong 0.32 QALYs, compared to the 4 years entecavir treatment (16,394 QALYs 
vs. 16,074 QALYs). The total cost per patient treated with peginterferon alfa-2a was 
US$22,221, and US$19,989 for patient treated with entecavir. The discounted incre-
mental cost per QALY gained for pegainterferon alfa-2a was US$6965. CONCLU-
SIONS: The results of the model suggest that 1 year pegainterferon alfa-2a improves 
health outcomes in a cost-effective manner compared with 4 years entecavir in the 
treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To estimate long-term cost-effectiveness of treatment of chronic hepa-
titis C (CHC) patients with peginterferon alfa-2a (180 mcg/week) versus peginterferon 
alfa-2b (1.5 mcg/kg/week) both in combination with ribavirin (800–1400 mg/day) 
from the Spanish National Healthcare System perspective. METHODS: A meta-
analysis of head-to-head randomized trials of peginterferon alfa-2a and peginterferon 
alfa-2b both plus ribavirin, evaluating sustained virological response (SVR) has been 
recently published. It showed RR = 1.11 (95%CI 1.04–1.19) for all genotypes, RR = 
1.21 (95%CI 1.03–1.42) for G-1/4, and RR = 1.11 (95%CI 1.02–1.22) for G-2/3. a 
Markov model with 7 health states was developed to simulate the disease progression 
of adult patients with CHC for a lifetime horizon. Efﬁ cacy, in terms of SVR, was 
calculated from the meta-analysis, showing a better SVR rate for peginterferon alfa-2a 
than for peginterferon alfa-2b: the absolute differences were of 6.0%; 7.6%; and 8.7% 
for all genotypes, G-1/4 and G-2/3 respectively. Transition probabilities and health 
states utilities were obtained from published literature. Health direct costs of pegin-
terferon + ribavirin (48 weeks for G-1/4 and 24 weeks for G-2/3) and of disease 
complications were collected from Spanish databases and studies ([c] 2010). The 
annual discount rate was 3.5% for costs and outcomes. RESULTS: Each patient 
gained 0.469, 0.600 and 0.685 life-years (LY) and 0.155, 0.198 and 0.227 quality-
adjusted life-years (QALY) with peginterferon alfa-2a in comparison with peginter-
feron alfa-2b, for all genotypes, G-1/4 and G-2/3 respectively. The savings per patient 
treated with peginterferon alfa-2a were c705, c672 and c1900, for all genotypes, 
G-1/4 and G-2/3, respectively. Peginterferon alfa-2a was the dominant treatment 
strategy (lower costs and higher efﬁ cacy than peginterferon alfa-2b treatment). 
CONCLUSIONS: Treatment of patients with chronic hepatitis C with peginterferon 
alfa-2a + ribavirin is a cost-effective strategy in comparison with peginterferon alfa-2b 
+ ribavirin for all genotypes, G-1/4 and G-2/3.
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KIOVIG FOR PRIMARY IMMUNODEFICIENCY: REDUCED INFUSION AND 
DECREASED COSTS PER INFUSION
Connolly M1, Simoens S2
1Global Market Access Solutions, St Prex, Switzerland; 2K.U. Leuven, Leuven, Belgium
OBJECTIVES: Kiovig is a new, ready-to-use 10% liquid immunoglobulin preparation 
that is medically indicated for the treatment of primary immunodeﬁ ciency. This study 
aims to conduct an economic evaluation which compares the intravenous immuno-
globulin (IVIg) preparations Kiovig, Multigam, and Sandoglobulin from the Belgian 
societal perspective. METHODS: Given that three prospective studies have observed 
no difference in outcomes, a cost-minimization analysis considered the differences in 
costs that can arise from these immunoglobulin products. a decision-analytic model 
simulated immunoglobulin treatment over a one-year time horizon. Cost items 
included immunoglobulin costs, pharmacy administration and nursing costs, mini-
forfait paid for hospital infusion, costs of adverse events, and lost productivity. Cost 
data were identiﬁ ed from published sources and Belgian hospital administrators. a 
probabilistic sensitivity analysis explored the impact of parameter uncertainty. The 
price year was 2009. RESULTS: Costs per infusion cycle in adult primary immuno-
deﬁ ciency patients were c1.046 (95% conﬁ dence interval: c1.006–1.093) with Kiovig; 
c1.102 (c1.064–1.147) with Multigam; and c1.147 (c1.108–1.193) with Sandoglobu-
lin. The average cost savings per infusion with Kiovig as compared to Multigam and 
Sandoglobulin amounted to c56 and c101 per infusion. CONCLUSIONS: Treatment 
costs with Kiovig were shown to be lower as compared to other IVIgs in Belgium. 
Reduced costs per infusion were attributed to lower costs associated with treating 
adverse events and the opportunity cost of nursing time and time off work for working 
adults.
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OBJECTIVES: To evaluate cost-effectiveness of pneumococcal non-typeable Hae-
mophilus Inﬂ uenza protein D conjugate vaccine(PHiD-CV), 7-valent pneumococcal 
conjugate vaccine(PCV7), and PCV13 in Taiwan. METHODS: An age-compartmen-
tal, deterministic, static cohort model simulated in a 198,733 birth cohort the disease 
process of invasive disease(ID, meningitis and bacteremia), community acquired 
pneumonia(CAP), and acute otitis media(AOM) over life-time. The model was devel-
oped by GlaxoSmithKline and adapted with local data. For base-case analysis for all 
vaccines, a 4-dose(3 + 1) schedule was assumed with 95% vaccine coverage. Cost and 
outcomes were analyzed from health care payer perspective with 3% discount rate. 
Herd protection on ID, limited cross protection against 6A and 19A, minimal estima-
tion of NTHi(non-typeable Haemophilis Inﬂ uenzae) infection rates in ID and CAP 
were assumed for base case. Costs for PHiD-CV, PCV7 and PCV13 were assumed 
parity at 3200 New Taiwan Dollar(NTD). Epidemiological and cost data were 
obtained from local disease burden study. Vaccine efﬁ cacy data were obtained from 
published sources. One way and probabilistic sensitivity analyses were conducted. 
RESULTS: Compared with PCV7, PHiD-CV is expected to prevent additional cases 
of 1 ID, 2,291 CAP and 63,597 AOM, with 548 additional quality-adjusted life-
years(QALY) gained with total saving of NTD 69,347,211. Compared with PCV13, 
PHiD-CV is expected to prevent less cases of 4 ID and 264 CAP, but expected to 
prevent additional 45,111 AOM cases. PHiD-CV is expected to provide additional 
181 QALY gained with total saving of NTD 14,532,124 compared to PCV13. Sensi-
tivity analyses show the results are most sensitive to the changes of AOM related 
parameters, but when the AOM related parameters were changed up to +/− 20%, 
PHiD-CV is still cost-saving to PCV7 and PCV 13. CONCLUSIONS: PHiD-CV is 
expected to provide more QALYs with potential saving of total health care cost 
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compared with PCV7 and PCV13. At price parity, PHiD-CV is cost-saving to PCV7 




K.U. Leuven, Leuven, Belgium
OBJECTIVES: Antibiotics have made a signiﬁ cant contribution to improving patient 
health, but policy makers and health care payers are concerned about the costs of 
antibiotics in addition to their effectiveness. This study aims to assess the value of 
antibiotics by examining published incremental cost-utility ratios of antibiotics. 
METHODS: Evidence was derived from cost-utility analyses of antibiotics included 
in the Tufts-New England Center Cost-Effectiveness Analysis Registry through Sep-
tember 2009. For each cost-utility analysis, the following variables were examined: 
publication year, target population, intervention type, country of patient sample, 
disease classiﬁ cation, prevention stage, funding source, study perspective, discounting, 
sensitivity analysis, incremental cost-utility ratio, and methodological quality. Evi-
dence of the value of antibiotics was summarized by calculating median incremental 
cost-utility ratios and frequency distributions. Associations between incremental cost-
utility ratios on the one hand and the prevention stage, study perspective and meth-
odological quality were examined by means of the Mann-Whitney U-test for ordinal 
variables. RESULTS: The analysis included 85 incremental cost-utility ratios from 23 
cost-utility analyses. The ﬁ ndings showed that 38.8% of incremental cost-utility ratios 
related to dominant antibiotics; 45.9% referred to antibiotics that improved effective-
ness, but also increased costs; and 15.3% related to dominated antibiotics. The median 
ratio was c748 per quality-adjusted life-year. Using threshold values of c20,000 per 
quality-adjusted life-year and c50,000 per quality-adjusted life-year, the probability 
that an antibiotic provides value for money was 64% and 67%, respectively. No 
statistically signiﬁ cant association was observed between incremental cost-utility ratios 
and the prevention stage (p = 0.119), study perspective (p = 0.285) or methodological 
quality (p = 0.146). CONCLUSIONS: The current evidence base suggests that the 
majority of antibiotics provide value for money.
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COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A PLUS 
RIBAVIRIN FOR TREATING CRONIC HEPATITIS C VIRUS INFECTION 
COMPARED WITH NO TREATMENT IN MEXICO
Carlos F1, DeHesa2
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OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2–3.0% 
worldwide (130–170 million people). a persistent infection develops in up to 85% of 
these patients, leading to chronic hepatitis C (CHC), a condition associated with 
serious liver-related complications. We aimed to perform an economic evaluation of 
peginterferon alpha-2a (PEG-IFN alpha-2a) plus ribavirin (RBV). METHODS: We 
developed a Markov model with 40 annual cycles to project cumulative cost and 
quality-adjusted life-years (QALY) for two identical cohorts of patients aged 40 years. 
One cohort received PEG-IFN alpha-2a 180 mcg per week plus daily doses of 
1200 mg of RBV during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. 
The other cohort did not receive any antiviral treatment. The analysis was performed 
under the perspective of national public health care system. Only direct medical costs 
were accounted for; these included acquisition cost of antiviral drugs and medical 
attention for health states incorporated into the model. Costs (expressed in 2010 
Euros) and QALY were discounted at an annual rate of 5%. Transition probabilities 
and utility scores were gathered from published literature and cost data was based on 
local sources and experts’ opinion. RESULTS: Average discounted costs were esti-
mated at c15,626 for PEG-IFN alpha-2a plus RBV and at c17,350 when no antiviral 
treatment is given to CHC patients, leading to overall savings of c1724 per patient. 
Without antiviral treatment, 9.9 QALY per patient are expected. There is a gain of 
2.2 QALY for patients who are treated. Results are robust to variations in model 
parameters. PEG-IFN alpha-2a plus RBV was both more effective and less costly than 
no treatment in more than half of the simulations performed in a probabilistic sensitiv-
ity analysis. CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy 
compared to given no antiviral treatment to CHC patients in Mexico.
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OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2–3.0% 
worldwide (130–170 million people). A persistent infection develops in up to 85% of 
these patients, leading to chronic hepatitis C (CHC), a condition associated with 
serious liver-related complications. Current standard of treatment includes Peginter-
feron (PEG-IFN) alpha plus ribavirin (RBV). We aimed to compare two different 
options of PEG-IFN alpha. METHODS: We developed a Markov model with 40 
annual cycles to project cumulative cost and quality-adjusted life-years (QALY) for 
two identical cohorts of moderate CHC patients without cirrhosis aged 40 years. One 
cohort received PEG-IFN alpha-2a 180 mcg per week and the other received PEG-IFN 
alpha-2b 1.5 mcg/Kg weekly, both combined with daily doses of 1,200 mg of RBV 
during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. The analysis was 
performed under the perspective of national public health care system. Only direct 
medical costs were accounted for; these included acquisition cost of antiviral drugs 
and medical attention for health states incorporated into the model. Costs (expressed 
in 2010 Euros) and QALY were discounted at an annual rate of 5%. Transition 
probabilities and utility scores were gathered from published literature and cost data 
was based on local sources and experts’ opinion. RESULTS: Average discounted costs 
were estimated at c16,854 for PEG-IFN alpha-2a plus RBV and at c18,247 for 
PEG-IFN alpha-2b plus RBV, leading to overall savings of c1,393 per patient when 
PEG-IFN alpha-2a is used. Discounted QALY were 12.29 for PEG-IFN alpha-2a and 
12.17 for PEG-IFN alpha-2b. Results are robust to variations in model parameters. 
CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy compared to 
given PEG-IFN alpha-2b treatment to CHC patients in Mexico.
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UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION 
IN THE NETHERLANDS
Rozenbaum MH1, Hak E1, Wilschut JC1, Postma MJ2
1University of Groningen, Groningen, Groningen, The Netherlands; 2University of Groningen, 
Groningen, The Netherlands
OBJECTIVES: To investigated the most important factors responsible for the large 
differences in previously estimated cost-effectiveness ratios and to update the cost-
effectiveness of rotavirus vaccination in the The Netherlands applying assumptions 
resulting from 2 consensus meetings with national and international experts in the 
ﬁ eld, from academia, clinical environments, industry and health policy. METHODS: 
We constructed a decision analytic model to compare the expected net costs and health 
beneﬁ ts over a period of 5 years in two hypothetical cohorts of 180,000 children 
(approximating the Dutch birth cohort), one being vaccinated and one unvaccinated. 
The base-case analysis reﬂ ected the most likely—but also overall conservative—esti-
mate of cost-effectiveness from the societal perspective. Robustness of the base-case 
result was investigated in sensitivity and scenario analyses. RESULTS: In the base-case 
analysis, it was estimated that approximately 59,495 RVGE cases would occur, result-
ing in 11,453 GP visits and 3,238 hospitalizations. With vaccination, approximately 
34,000 cases of RVGE cases are averted corresponding to a total QALY gain of 167. 
Assuming a total cost of vaccination of c75, vaccination would result in cost-effec-
tiveness of c30,540 per QALY gained (c152 per case averted). Results were sensitive 
to the number of deaths due to RVGE, inclusion of potential herd protection, inclusion 
of QALY decrements of care givers, further potential tender price reduction and the 
exact discount rate used. CONCLUSIONS: Our economic analysis indicates that a 
potential national immunization programme against rotavirus can be considered cost-
effective if applying a threshold of c50,000 per QALY for the The Netherlands.
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OBJECTIVES: Raltegravir (Merck & Co., Inc.) is an inhibitor of HIV type 1 (HIV-1) 
integrase, and is the ﬁ rst drug in a new class of therapy known as the integrase inhibi-
tors. Raltegravir has already shown to be cost-effective in HIV treatment experienced 
patients in Hungary. The objective of the current study is to assess if the ﬁ rst line use 
of raltegravir is cost-effective compared to its use in rescue therapy from the Hungarian 
public payer perspective. METHODS: First line use of raltegravir was evaluated versus 
a protease inhibitor (PI) using a Markov model. Raltegravir was also included as a 
3rd line therapy within the model arm that initiates on a PI. The Markov process 
comprised a three stage continuous-time model representing successive HIV therapies 
over a patient’s life-time. Patients moved between 18 health states—based on CD4 
and HIV RNA levels. Patients progressed to the next stage after they either failed 
current therapy or discontinued for toxicity reasons. At any time, patients could 
develop acquired immunodeﬁ ciency syndrome (AIDS), suffer from a coronary heart 
disease (CHD) event and/or experience other adverse events. Mortality was also 
captured in the model. RESULTS: The incremental cost-effectiveness ratio (ICER) for 
initiating therapy with raltegravir versus using it as a rescue therapy was 4,075 million 
HUF per quality adjusted life-year gained (QALY), equivalent to $16,830/QALY. The 
model predicted lower cumulative incidence of CHD in the raltegravir arm versus the 
PI arm. (15.1% versus 16.1%). The model predicted that patients initiating on ralte-
gravir therapy have longer life expectancy than patients starting with PI treatment 
over a 50-year time horizon (18.74 versus 17.17 years). CONCLUSIONS: Our long 
term economic model suggests that it is cost-effective to use raltegravir early in HIV 
therapy versus in patients who have experienced multiple failures.
